Generic subscription services like Mark Cuban’s promise cheaper drugs — but will it work?

The Latest

• 

  Q&A

  How a speech analysis tool could transform diagnosis and research for Alzheimer’s and beyond

  WinterLight’s machine learning platform assesses speech to more accurately identify neurodegenerative diseases.

  Biotech

• 

  Q&A

  Personalized data could bring PhysIQ to the forefront of clinical trial evolution

  The digital medicine company’s chief strategy officer, John Varaklis, explains how its analytic predictive platform could lead to safer and quicker clinical trials.

  Pharma

• 

  What’s next for Biogen? Here’s what executives are saying

  A trickling launch for Aduhelm and a middling earnings report give Biogen executives a lot to talk about. Is there hope?

  Biotech

• 

  Q&A

  Lupus discovery lends clues to the fight against long COVID

  So far, pharma has yet to provide an answer for long COVID. But award-winning lupus research by Yale professor Akiko Iwasaki could help lead the way.

  Patient

• 

  Podcast

  Woman of the Week: Applied BioMath's Katie Williams

  The 2022 president of Women in Bio is equal parts math and gender parity evangelist. 

  Leadership

• 

  Democrats think they've found a balance between drug innovation and pricing negotiation

  A look at Congress’ push to pass drug pricing reform and why the latest attempt could actually succeed.

  Biotech

• 

  The earlier the better: New consortium leverages infant screening to accelerate treatment

  Inozyme Pharma has joined a genomic sequencing program developing a novel rapid test for 388 genetic diseases.

  Biotech

• 

  A 'total waste'? Drug developers worry if two decades of Alzheimer's research were pointed at the wrong targets

  The latest trial failures in Alzheimer's have shown cracks in the foundation of ingrained theories like amyloid plaque clearance. What will it take to move forward?

  Biotech

• 

  Q&A

  Behind Pfizer's new quest to target a 'transformation' in pharma

  A combined venture with Roivant — called Priovant Therapeutics — is looking to be a forerunner in the burgeoning autoimmune disease market.

  Biotech

• 

  With big changes ahead for J&J and Novartis, here's what the companies' execs are talking about

  Both J&J and Novartis are making — or considering — big shifts in their fundamental company makeup.

  Pharma

• 

  Moderna's next vax target? A little-known cause of birth defects

  How the mRNA-based biotech is developing the first-ever prophylactic for a devastating virus.

  Biotech

• 

  By the numbers: The rising danger of superbugs

  A look at how the COVID-19 pandemic exacerbated one of the world’s greatest public health concerns.

  Biotech

• 

  Podcast

  Woman of the Week: Vaxxinity's Mei Mei Hu

  Mei Mei Hu is looking to lead a third biologic ‘revolution’ by developing vaccines for chronic diseases.

  Biotech

• 

  Pfizer's former R&D head takes on drug pricing misconceptions in new book

  John LaMattina has something to say about the industry — and he hopes patients are listening.

  Commercialization

• 

  Biotech R&D spending has skyrocketed, and so have opportunities for savings

  With R&D costs on the rise, biotechs are embracing new strategies and technologies to make spending more efficient.

  Biotech

• 

  Making moves: Agios, BeiGene, Biocom California and more announce new key hires

  The latest executive personnel changes from around the industry.

  Biotech

• 

  Q&A

  First 90 Days: Anjarium Biosciences' Stephen Yoo

  The incoming CEO aims to build on the buzz around the company’s leading-edge gene therapy tech.

  Biotech

• 

  Alkermes looks to fill cancer treatment gaps with new immune pathways

  The company’s chief medical officer discusses its lead candidate and how it fits into wider oncology trends.

  Biotech

• 

  Profile

  The power of the underdog: A rare disease nonprofit working to help patients win against the odds

  Elizabeth Izard Apelles is finding innovative ways to champion rare disease patients through an emerging platform from Honeycomb Health.

  Leadership

• 

  Q&A

  Janssen extends LGBTQ mental health outreach beyond Pride Month

  The pharma giant’s ‘Depression looks like me’ campaign assembles a ‘one stop shop’ of resources to help combat high rates of severe depression in the LGBTQ community.

  Commercialization

• 

  Podcast

  Woman of the Week: Kura Oncology's Kirsten Flowers

  How the chief commercial and corporate strategy officer is embracing a ‘full-cup’ philosophy to build a better leadership toolbox.

  Biotech

• 

  Precision closes in on what could become the first 'off-the-shelf' CAR-T cell therapy

  Precision BioSciences’ CEO discusses the company’s potentially groundbreaking cancer treatment.

  Biotech

• 

  Q&A

  COVID won't evolve to become 'less deadly' — and RedHill is prepping for the long haul

  RedHill Biopharma’s chief operating officer, Guy Goldberg, says the company’s oral COVID-19 therapy could still be needed on a global scale.

  Commercialization

• 

  Why a 'fundamental shift' in regulatory submissions is on the way

  Deloitte's senior manager of R&D and regulatory practices explains how technology and strategy must converge to smooth out the bulky drug approval process.

  Biotech

• 

  Behind the new topical treatment set to disrupt the psoriasis market

  Phil Brown, Dermavant’s chief medical officer, discusses VTAMA — the first topical cream approved for psoriasis in 25 years.

  Commercialization